Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
1998-09-02
2002-04-23
Dees, Jose′ G. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C424S464000, C424S465000, C424S489000, C514S769000, C514S770000, C514S951000, C514S975000
Reexamination Certificate
active
06376481
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to sterol ester in the form of a tablet that is suitable for reducing cholesterol levels in patient.
BACKGROUND OF THE INVENTION
Several reports have described the use of plant-sterols (i.e., &bgr;-sitosterol) as dietary supplements for the reduction of serum cholesterol levels. It is generally accepted that the sitosterol family of plant sterols reduces serum cholesterol by inhibiting the intestinal absorption of cholesterol. More recently, &bgr;-sitosterol's saturated equivalent, &bgr;-sitostanol, has been shown to be more effective in the reduction of intestinal cholesterol absorption. Furthermore, sitostanol itself is virtually unabsorbed, so it does not contribute at all to in vivo serum cholesterol concentration upon consumption. These observations make &bgr;-sitostanol an attractive candidate as a dietary supplement for reduction of serum cholesterol levels.
Typically it has been necessary to incorporate the sterol ester in a suitable material such as a margarine, in which the waxy nature of the sterol ester can be tolerated. There have been reports that describe how the esterification of sterols (stanols) to a fatty acid or an edible oil produces a sterol (stanol) ester with improved micelle solubility characteristics. For example, when sitostanol is esterified to edible oil such as rapeseed oil, a wax-like mixture of fatty acid esters with excellent lipid solubility results. These sterol esters are conveniently incorporated into food products such as margarine.
However there is a continuing need for a tableted form of the sterol ester.
SUMMARY OF THE INVENTION
The present invention is directed to a solid oral dosage form having a compressed free-flowing powder, which includes an effective amount of sterol, stanol or their corresponding acid ester to reduce cholesterol, about 5 to about 75 milligrams per dosage form of a support with a surface area range of from about 100 to 350 square meters/gram, wherein the sterol, stanol or their corresponding acid ester is in a molten form when loaded onto the support, and a monofunctional surfactant and a polyfunctional surfactant, wherein the polyfunctional surfactant is a polyoxyethylene derivative of the monofunctional surfactant.
The present invention also provides a method for producing a solid oral dosage form that includes heating a sterol, stanol or their corresponding acid ester at a temperature of from about 45 to about 100° C. to provide the sterol, stanol or their corresponding acid ester in a molten form, providing a monofunctional surfactant and a polyfunctional surfactant, wherein the polyfunctional surfactant is a polyoxyethylene derivative of the monofunctional surfactant, admixing the molten sterol, stanol or their corresponding acid ester and the monofunctional surfactant and the polyfunctional surfactant to form a sterol, stanol or their corresponding acid ester-surfactant mixture, providing a support with a surface area of from about 100 to about 350 square meters per gram, adding a sufficient amount of the support to the molten sterol, stanol or their corresponding acid ester-surfactant mixture to form a flowable powder, and optionally compressing the flowable powder to form a tablet.
REFERENCES:
patent: 3004043 (1961-10-01), Stern
patent: 3203862 (1965-08-01), Jones
patent: 3495011 (1970-02-01), Fossel
patent: 3865939 (1975-02-01), Jandacek
patent: 3881005 (1975-04-01), Thakkar et al.
patent: 4160850 (1979-07-01), Hallstron et al.
patent: 4195084 (1980-03-01), Ong
patent: 4238520 (1980-12-01), Miller et al.
patent: 4588717 (1986-05-01), Mitchell
patent: 4705875 (1987-11-01), Mitchell
patent: 4824672 (1989-04-01), Day et al.
patent: 4831058 (1989-05-01), Pankhania et al.
patent: 4883788 (1989-11-01), Day et al.
patent: 5306514 (1994-04-01), Letton et al.
patent: 5306515 (1994-04-01), Letton et al.
patent: 5308639 (1994-05-01), Fung
patent: 5326825 (1994-07-01), Nasman et al.
patent: 5338563 (1994-08-01), Mikulka et al.
patent: 5472728 (1995-12-01), Miller et al.
patent: 5502045 (1996-03-01), Miettinen et al.
patent: 5514398 (1996-05-01), Imai et al.
patent: 5629359 (1997-05-01), Peeters et al.
patent: 5747464 (1998-05-01), See
patent: 5770254 (1998-06-01), Izzo et al.
patent: 5932562 (1999-08-01), Ostlund, Jr.
patent: 6025010 (2000-02-01), Reddy
patent: 6025348 (2000-02-01), Goto et al.
patent: 6054144 (2000-04-01), Burruano et al.
patent: 6087353 (2000-07-01), Stewart et al.
patent: 6110502 (2000-08-01), Burruano et al.
patent: 6242001 (2001-06-01), Bruce et al.
patent: 0 608 600 (1994-03-01), None
patent: 0 771 531 (1997-07-01), None
patent: 0 947 197 (1999-10-01), None
patent: 284 814 (1972-09-01), None
patent: 1 413 102 (1975-05-01), None
patent: 1 598 638 (1981-09-01), None
patent: 95/00158 (1995-05-01), None
patent: 96/38047 (1996-05-01), None
patent: 98/06714 (1998-02-01), None
patent: WO 99/56729 (1999-11-01), None
patent: WO 99/63841 (1999-12-01), None
Editors: Wade, Ailey and Weller, Paul J.; Polyoxyethylene Sorbitan Fatty Acid Esters and Sorbitan Esters (Sorbitan Fatty ACid Esters); Handbook of Pharmaceutical Excipients, 2nd Edition, 1994, pp. 375-378 and pp. 473-476, respectively.
U.S. application No. 09/025,952, filed Feb. 9, 1998. Status Allowed—“Method for Producing Water Dispersible Sterol Formulations”.
U.S. application No. 09/185,788, filed Nov. 4, 1998. Status Allowed—Issue fee Paid Jan. 11, 2000—“Method for Producing Water Dispersible Sterol Formulations”.
U.S. application No. 09/200,623, filed Nov. 30, 1998. Status Pending—“Method for Producing Dispersible Sterol and Stanol Compounds”.
Slover et al., “Lipids in Margarines and Margarine-Like Foods”, JAOCS, vol. 62, 4/95.
Westrate and Meijer, “Plant sterol-enriched margarines and reduction of plasma total-and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects”, Eur. J. of Clin. Nut., 1998.
Bruce Richard D.
Higgins John D.
Martellucci Stephen A.
Choi Frank
Dees Jose′ G.
Mc-Neil-PPC, Inc.
Tracy Timothy E.
LandOfFree
Sterol esters in tableted solid dosage forms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sterol esters in tableted solid dosage forms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sterol esters in tableted solid dosage forms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2825184